Alnylam Pharmaceuticals, Inc. (ALNY) Stock
ALNY Key Statistics
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
CEO: Yvonne L. Greenstreet. Company website
ALNY — Frequently Asked Questions
What is the ALNY stock price today?
Alnylam Pharmaceuticals, Inc. (ALNY) trades at $239.56, down 2.42% on the day, as of Sep 20, 2026 15:01 UTC.
What is Alnylam Pharmaceuticals, Inc.'s market cap?
Alnylam Pharmaceuticals, Inc. has a market capitalisation of $32.06B, calculated from the live ALNY share price and shares outstanding.
What is the P/E ratio of ALNY?
ALNY trades at a trailing P/E of 40.47, from earnings per share of $5.92 over the last twelve months.
How much revenue does Alnylam Pharmaceuticals, Inc. make?
Alnylam Pharmaceuticals, Inc. generated revenue of $4.80B over the trailing twelve months, which puts the stock at 6.67 times sales.
What is the 52-week range for ALNY?
ALNY has traded between $200.02 and $495.55 over the past 52 weeks, and the last price is 51.7% below that high.
Is Alnylam Pharmaceuticals, Inc. profitable?
Yes. Alnylam Pharmaceuticals, Inc. keeps 16.82% of revenue as net income over the trailing twelve months.
What is the analyst price target for ALNY?
Wall Street analysts rate ALNY Buy, with an average price target of $347.33, 45.0% above the current price.
What sector is Alnylam Pharmaceuticals, Inc. in?
Alnylam Pharmaceuticals, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Alnylam Pharmaceuticals, Inc.?
Yvonne L. Greenstreet is the chief executive of Alnylam Pharmaceuticals, Inc., which employs 2,500 people.
Where can I track ALNY in real time?
QFI Terminal shows ALNY with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ALNY live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ALNY in Terminal See plans